Related Experiment Video
Updated: Dec 7, 2025

08:20
Genome Engineering of Primary Human B Cells Using CRISPR/Cas9
Published on: November 3, 2020
6.8K
Easy and robust electrotransfection protocol for efficient ectopic gene expression and genome editing in human B
Reynand Jay Canoy1,2, Franck André1, Anna Shmakova1,3
1UMR 9018, CNRS, Univ. Paris-Sud, Université Paris Saclay, Institut Gustave Roussy, 94805, Villejuif, France.
Gene Therapy
|October 1, 2020
Summary
We developed an efficient electrotransfection protocol for B cells, improving genome editing and gene expression studies. This cost-effective method achieves high transfection and viability rates for various B-cell types.
Area of Science:
- Immunology
- Molecular Biology
- Biotechnology
Background:
- Transfecting B-cell lines and primary peripheral blood mononuclear cells (PBMCs) is challenging, hindering genome editing and gene expression studies.
- Existing methods are often inefficient, costly, or require specialized equipment, limiting their widespread application.
Purpose of the Study:
- To develop a novel, efficient, and reproducible electrotransfection protocol for various B-cell types.
- To optimize conditions for high transfection and cell viability using cost-effective reagents and standard equipment.
Main Methods:
- Electrotransfection of lymphoblastoid cells, B-cell lymphoma, leukemia cell lines, and primary B cells from PBMCs.
- Optimization of salt concentration in the electrotransfection medium and plasmid amount.
- Validation through the generation of a TP53-deficient cell line (TP53-/- RPMI8866).
Main Results:
- Achieved routine transfection rates of approximately 79% and viability rates of 58%.
- The protocol is effective for both small and large plasmids.
- Successfully generated a TP53-/- RPMI8866 lymphoblastoid cell line.
Conclusions:
- The developed electrotransfection protocol offers an efficient, reproducible, and cost-effective solution for B-cell manipulation.
- This method facilitates genome editing, gene silencing, and ectopic gene expression in B cells.
- The validated protocol and generated cell line will aid future research in hematological and blood cancers.

